Post-Covid-19 condition in children and adolescents from a cohort in Puebla, Mexico: Prevalence and risk factors.
−ACERCA DE LA PORTADA−  El virus Epstein-Barr (EBV) es un gamma herpes virus que afecta humanos. La infección se adquiere principalmente durante la infancia o adolescencia; se presenta de manera asintomática o como un trastorno linfoproliferativo autolimitado que no requiere atención clínica. Sin embargo, afecta a más del 95% de la población adulta mundial y corresponde a uno de los virus oncogénicos más comunes en la especie humana: en promedio, cada año se asocia con 200,000 casos de cáncer. Interesantemente, solo un pequeño porcentaje de individuos infectados desarrolla procesos malignos, normalmente hospederos inmunocomprometidos o inmunodeficientes. EBV tiene un tropismo casi exclusivo por células B y de manera general la infección conduce a un estado latente o lítico, a partir de los cuales es posible desarrollar enfermedades y complicaciones. Las células citotóxicas NK y T CD8+ son los principales agentes inmunológicos que controlan y eliminan la infección por EBV. En este contexto, variantes genéticas que comprometan el desarrollo, proliferación, diferenciación, coestimulación y/o activación de células NK y T CD8+ predisponen al desarrollo de neoplasias o trastornos linfoproliferativos. Específicamente, se ha descrito la deficiencia, haploinsuficiencia o desregulación de ciertas proteínas citoplasmáticas, receptores de membrana, ligandos y transportadores de iones que afectan la función efectora de las células citotóxicas, y resultan en las secuelas más graves por EBV. Sin duda, el conocimiento ganado en este tema seguirá contribuyendo a diagnósticos más oportunos y el desarrollo de mejores estrategias terapéuticas en la clínica.     Breve descripción de la portada: Dres. Arturo Gutiérrez Guerrero, Sara Elva Espinosa Padilla y Saúl Oswaldo Lugo Reyes.   Agradecimiento especial por la elaboración y diseño de la portada: DG. Diana Gabriela Salazar Rodríguez.
PDF (Spanish)
XML (Spanish)

Keywords

Enfermedad post-COVID
Infección por SARS-CoV-2
Prevalencia
Factores de riesgo
Síntomas frecuentes

Abstract

Background: The WHO defines a post-COVID-19 condition as that which occurs in individuals with a history of SARS-CoV2 infection, 3 months after the onset of COVID19 with symptoms that last at least 2 months.

Objective: To determine the prevalence and risk factors of the post-COVID-19 condition of children and adolescents from a cohort

Methods: Observational and analytical cohort study. Statistical analysis: percentages, frequencies, averages. Odds ratio, Chi square. Multiple binary logistic regression. Statistical Package, for the Social Sciences 23.

Results: Prevalence of the post-COVID-19 condition, 14.8%. 175 patients, 26 developed post-COVID-19 condition, mean age 5.9 years (SD5.05), sex: 27% men, 73% women, frequent symptoms: fatigue, runny nose, muscle pain, dyspnea. Symptoms associated with post-COVID-19 condition: Muscle pain OR 27 p=0.000(IC95%5.2-139), dysgeusia OR 19 p=0.012(IC95% 1.9-19) fatigue OR 5 p=0.001(IC95%1.9-13.5) . Associated risk factors: female OR3.58p=0.023(95%CI1.19-10.71), comorbidities OR 24.5p=0.000(95%CI7.52-79), allergic rhinitis OR8.7p=0.000 (95%CI2.66-28.87) atopic dermatitis OR9. 58p=0.016 (95%CI 1.51-60.5).Conclusions: Although the majority of children infected with SARS-CoV2 recover completely, some of them will develop a post-COVID-19 condition, knowing the most frequent symptoms and associated factors, will allow a better evaluation, for its opportune detection and effective treatment.

PDF (Spanish)
XML (Spanish)

References

-Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis 2021 ;53(10):737-754. doi: 10.1080/23744235.2021.1924397.

-Pazukhina E, Andreeva M, Spiridonova E, et al. Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Med 2022 ;20(1):244. doi: 10.1186/s12916-022-02448-4.

-Stephenson T, Allin B, Nugawela MD, et al. Long COVID (post-COVID-19 condition) in children: a modified Delphi process. Arch Dis Child 2022 ;107(7):674-680. doi: 10.1136/archdischild-2021-323624.

-Izquierdo-Pujol J, Moron-Lopez S, Dalmau J, et al. Post COVID-19 Condition in Children and Adolescents: An Emerging Problem. Front Pediatr 2022 ;10:894204. doi: 10.3389/fped.2022.894204.

- Burki T. Clinical case definition of post-COVID-19 condition in children: a good start, but improvements are needed. Lancet Respir Med 2023 ;11(4):314. doi: 10.1016/S2213-2600(23)00081-4.

-Zimmermann P, Pittet LF, Curtis N. How Common is Long COVID in Children and Adolescents? Pediatr Infect Dis J 2021 ;40(12):e482-e487. doi: 10.1097/INF.0000000000003328.

-Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and clinical presentation of long COVID in children: a systematic review. Eur J Pediatr. 2022 ;181(12):3995-4009. doi: 10.1007/s00431-022-04600-x.

-Funk AL, Kuppermann N, Florin TA, et al. Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection. JAMA Netw Open 2022;5(7):e2223253. doi:10.1001/jamanetworkopen.2022.23253

-Rao S, Lee GM, Razzaghi H, et al. Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. JAMA Pediatr 2022;176(10):1000–1009. doi:10.1001/jamapediatrics.2022.2800

- WM A.World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects JAMA 2013; 310 (20): 2191-2194. doi:10.1001/jama.2013.281053

- Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep 2022 ;12(1):9950. doi: 10.1038/s41598-022-13495-5.

- Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. Acta Paediatr 2021 ;110(7):2208-2211. doi: 10.1111/apa.15870.

- Zimmermann P, Pittet LF, Curtis N. How Common is Long COVID in Children and Adolescents? Pediatr Infect Dis J 2021; 40(12):e482-e487. doi: 10.1097/INF.0000000000003328.

- Osmanov IM, Spiridonova E, Bobkova P, et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J 2022 ;59(2):2101341. doi: 10.1183/13993003.01341-2021.

- Kikkenborg Berg S, Dam Nielsen S, Nygaard U, et al. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health 2022;6(4):240-248. doi: 10.1016/S2352-4642(22)00004-9. (15)

- Kikkenborg Berg S, Palm P, Nygaard U, Bundgaard H, et al. A. Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health 2022 ;6(9):614-623. doi: 10.1016/S2352-4642(22)00154-7.

- Selvakumar J, Havdal LB, Drevvatne M, et al . Prevalence and Characteristics Associated With Post-COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults. JAMA Netw Open 2023 ;6(3):e235763. doi: 10.1001/jamanetworkopen.2023.5763.

- Kikkenborg Berg S, Dam Nielsen S, Nygaard U, et al. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health 2022 ;6(4):240-248. doi: 10.1016/S2352-4642(22)00004-9.

-Asadi-Pooya AA, Nemati H, Shahisavandi M, et al. Long COVID in children and adolescents. World J Pediatr 2021 Oct;17(5):495-499. doi: 10.1007/s12519-021-00457-6.

-Ludvigsson JF.Case report and systenmatic review suggest that children may experience similar long-term effects to adults after clinical COVID. Acta Paediatr 2021;110(3):914-921. doi:10.1111/apa.15673.

-Moreno-Pérez O, Merino E, Leon-Ramírez JM, et al. Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect 2021; 82(3):378-383. doi:10.1016/j.jinf.2021.01.004

-Munblit D, Greenhawt M, Brough HA, et al. Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics. Pediatr Allergy Immunol 2022 ;33(10):e13851. doi: 10.1111/pai.13851.

-Crook H, Raza S, Nowell J, Young M, Edison P. Long covid:mecanismos factores de riesgo y manejo.BMJ 2021;374: n168

- Fainardi V, Meoli A, Chiopris G, et al. Long COVID in Children and Adolescents. Life (Basel) 2022 ;12(2):285. doi: 10.3390/life12020285.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2023 Revista Alergia México

Downloads

Download data is not yet available.